Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/27204| Title: | Cardiovascular toxicity of targeted therapies for cancer: An overview of systematic reviews. | Authors: | Brown M.R.;Vajdic C.M.;Delaney G.P.;Hong S.;Hunt L.;Webber K. ;Pearson S.-A.;Van Leeuwen M.T.;Luu S.;Gurney H. | Institution: | (Van Leeuwen, Luu, Pearson, Hong, Vajdic) Centre for Big Data Research in Health, University of New South Wales, Sydney, NSW, Australia (Gurney, Brown) Faculty of Medicine and Health Sciences, Macquarie University, Sydney, NSW, Australia (Webber) Department of Oncology, Monash Health, Clayton, VIC, Australia (Webber) School of Clinical Sciences, Monash University, Clayton, VIC, Australia (Hunt) Cancer Voices NSW, Milsons Point, New South Wales, Australia (Hong) Division of Oncology-Haematology, Department of Internal Medicine, National Health Insurance Service Ilsan Hospital, Goyang, South Korea (Delaney) Liverpool Cancer Therapy Centre, Liverpool, NSW, Australia (Delaney) Collaboration for Cancer Outcomes Research and Evaluation, Ingham Institute for Applied Medical Research, Liverpool, NSW, Australia (Delaney) South Western Sydney Clinical School, University of New South Wales, Liverpool, NSW, Australia | Issue Date: | 24-Feb-2021 | Copyright year: | 2021 | Publisher: | Oxford University Press | Place of publication: | United Kingdom | Publication information: | JNCI Cancer Spectrum. 4 (6) (no pagination), 2021. Article Number: pkaa076. Date of Publication: 2021. | Journal: | JNCI Cancer Spectrum | Abstract: | Background: Several targeted therapies for cancer have been associated with cardiovascular toxicity. The evidence for this association has not been synthesized systematically nor has the quality of evidence been considered. We synthesized systematic review evidence of cardiovascular toxicity of individual targeted agents. Method(s): We searched MEDLINE, Embase, and the Cochrane Database of Systematic Reviews for systematic reviews with meta-analyses of cardiovascular outcomes for individual agents published to May 2020. We selected reviews according to prespecified eligibility criteria (International Prospective Register of Systematic Reviews CRD42017080014). We classified evidence of cardiovascular toxicity as sufficient, probable, possible, or indeterminate for specific cardiovascular outcomes based on statistical significance, study quality, and size. Result(s): From 113 systematic reviews, we found at least probable systematic review evidence of cardiovascular toxicity for 18 agents, including high- and all-grade hypertension for bevacizumab, ramucirumab, axitinib, cediranib, pazopanib, sorafenib, sunitinib, vandetanib, aflibercept, abiraterone, and enzalutamide, and all-grade hypertension for nintedanib; high- and all-grade arterial thromboembolism (includes cardiac and/or cerebral events) for bevacizumab and abiraterone, high-grade arterial thromboembolism for trastuzumab, and all-grade arterial thromboembolism for sorafenib and tamoxifen; high- and all-grade venous thromboembolism (VTE) for lenalidomide and thalidomide, high-grade VTE for cetuximab and panitumumab, and all-grade VTE for bevacizumab; high- and all-grade left ventricular ejection fraction decline or congestive heart failure for bevacizumab and trastuzumab, and all-grade left ventricular ejection fraction decline/ congestive heart failure for pazopanib and sunitinib; and all-grade corrected QT interval prolongation for vandetanib. Conclusion(s): Our review provides an accessible summary of the cardiovascular toxicity of targeted therapy to assist clinicians and patients when managing cardiovascular health.Copyright © 2020 Oxford University Press. All rights reserved. | DOI: | http://monash.idm.oclc.org/login?url= http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1093/JNCICS/PKAA076 |
ISSN: | 2515-5091 (electronic) | URI: | https://repository.monashhealth.org/monashhealthjspui/handle/1/27204 | Type: | Review | Subjects: | meta analysis *multiple myeloma/dt [Drug Therapy] observational study oncology *ovary cancer/dt [Drug Therapy] peer review phase 2 clinical trial (topic) phase 3 clinical trial (topic) priority journal *prostate cancer/dt [Drug Therapy] QT prolongation/si [Side Effect] randomized controlled trial (topic) review systematic review venous thromboembolism/si [Side Effect] abiraterone/ae [Adverse Drug Reaction] abiraterone/ct [Clinical Trial] abiraterone/dt [Drug Therapy] aflibercept/ae [Adverse Drug Reaction] aflibercept/ct [Clinical Trial] androgen receptor/ec [Endogenous Compound] axitinib/ae [Adverse Drug Reaction] axitinib/ct [Clinical Trial] bevacizumab/ae [Adverse Drug Reaction] bevacizumab/ct [Clinical Trial] bevacizumab/dt [Drug Therapy] cediranib/ae [Adverse Drug Reaction] cediranib/ct [Clinical Trial] cetuximab/ae [Adverse Drug Reaction] cetuximab/ct [Clinical Trial] cytochrome P450 family 17/ec [Endogenous Compound] enzalutamide/ae [Adverse Drug Reaction] enzalutamide/ct [Clinical Trial] enzalutamide/dt [Drug Therapy] epidermal growth factor receptor 2/ec [Endogenous Compound] estrogen receptor alpha/ec [Endogenous Compound] estrogen receptor beta/ec [Endogenous Compound] Flt3 ligand/ec [Endogenous Compound] lenalidomide/ae [Adverse Drug Reaction] lenalidomide/ct [Clinical Trial] lenalidomide/dt [Drug Therapy] nintedanib/ae [Adverse Drug Reaction] nintedanib/ct [Clinical Trial] panitumumab/ae [Adverse Drug Reaction] panitumumab/ct [Clinical Trial] pazopanib/ae [Adverse Drug Reaction] pazopanib/ct [Clinical Trial] platelet derived growth factor alpha receptor/ec [Endogenous Compound] platelet derived growth factor beta receptor/ec [Endogenous Compound] protein Ret/ec [Endogenous Compound] Raf protein/ec [Endogenous Compound] ramucirumab/ae [Adverse Drug Reaction] ramucirumab/ct [Clinical Trial] sorafenib/ae [Adverse Drug Reaction] sorafenib/ct [Clinical Trial] sorafenib/dt [Drug Therapy] sunitinib/ae [Adverse Drug Reaction] sunitinib/ct [Clinical Trial] tamoxifen/ae [Adverse Drug Reaction] tamoxifen/ct [Clinical Trial] tamoxifen/dt [Drug Therapy] thalidomide/ae [Adverse Drug Reaction] thalidomide/ct [Clinical Trial] thalidomide/dt [Drug Therapy] transcription factor/ec [Endogenous Compound] trastuzumab/ae [Adverse Drug Reaction] trastuzumab/ct [Clinical Trial] trastuzumab/dt [Drug Therapy] unclassified drug vandetanib/ae [Adverse Drug Reaction] vandetanib/ct [Clinical Trial] vandetanib/dt [Drug Therapy] vasculotropin A/ec [Endogenous Compound] vasculotropin receptor 1/ec [Endogenous Compound] vasculotropin receptor 3/ec [Endogenous Compound] cytochrome P450 family 17a1/ec [Endogenous Compound] lymphoid transcription factor ikzf1/ec [Endogenous Compound] lymphoid transcription factor ikzf3/ec [Endogenous Compound] *molecularly targeted therapy arterial thromboembolism/si [Side Effect] *breast cancer/dt [Drug Therapy] cardiology cardiotoxicity/si [Side Effect] *castration resistant prostate cancer/dt [Drug Therapy] clinician Cochrane Library cohort analysis congestive heart failure/si [Side Effect] controlled study drug megadose Embase female general practice heart left ventricle ejection fraction human hypertension/si [Side Effect] low drug dose *lung cancer/dt [Drug Therapy] male Medline drug megadose Embase female general practice heart left ventricle ejection fraction human hypertension / side effect low drug dose *lung cancer / *drug therapy male Medline meta analysis *molecularly targeted therapy *multiple myeloma / *drug therapy observational study oncology *ovary cancer / *drug therapy peer review phase 2 clinical trial (topic) phase 3 clinical trial (topic) priority journal *prostate cancer / *drug therapy QT prolongation / side effect randomized controlled trial (topic) Review systematic review venous thromboembolism / side effect *breast cancer / *drug therapy cardiology arterial thromboembolism / side effect cardiotoxicity / side effect *castration resistant prostate cancer / *drug therapy clinician Cochrane Library cohort analysis congestive heart failure / side effect controlled study |
Type of Clinical Study or Trial: | Systematic review and/or meta-analysis |
| Appears in Collections: | Articles |
Show full item record
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.